This item still needs to be validated !
Title: N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group
Authors: Paridaens, Robert ×
Mouridsen, H T
Palshof, T
Cocconi, G
Van Oosterom, Allan
Rotmensz, N
Sylvester, R
Heuson, J C
Rozencweig, M #
Issue Date: Jan-1982
Series Title: European journal of cancer & clinical oncology vol:18 issue:1 pages:67-70
Abstract: Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.
ISSN: 0277-5379
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Department of Oncology - miscellaneous
Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science